Advanced glycoxidation products and impaired diabetic wound healing

Wound Repair and Regeneration

Volumn 17, Issue 4, 2009, Pages 461-472

  Peppa, Melpomeni ^a   Stavroulakis, Panagiotis ^a   Raptis, Sotirios A ^a,b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b Hellenic National Diabetes Center   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; BASIC FIBROBLAST GROWTH FACTOR; CELL SURFACE RECEPTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

CELL PROLIFERATION; COOKING; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC NEUROPATHY; EPITHELIZATION; FIBROBLAST; FOOD PROCESSING; FOOT ULCER; GRANULATION TISSUE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY INFILTRATE; KERATINOCYTE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; SKIN; STREPTOZOCIN DIABETES; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANIMALS; DIABETES COMPLICATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MICE; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; WOUND HEALING;

EID: 67651180895     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2009.00518.x     Document Type: Review

References (121)

1. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003 361 : 1545 51.
2. Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care 2005 28 : 551 4.
3. Katz IA, Harlan A, Miranda-Palma B, Prieto-Sanchez L, Armstrong DG, Bowker JH, Mizel MS, Boulton AJ. A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers. Diabetes Care 2005 28 : 555 9.
4. Boulton AJ, Kirsner RS, Vileikyte L, Boulton AJ. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 2004 351 : 48 7.
5. American Diabetes Association. Peripheral arterial disease in people with diabetes Diabetes Care 2003 26 : 3333 41.
6. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, Nowygrod S, Wolf BM, Caliste X, Yan SF, Stern DM, Schmidt AM. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001 159 : 513 25.
7. Peppa M, Brem H, Ehrlich PM, Zhang JG, Cai W, Li Z, Croitoru A, Thung S, Vlassara H. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003 52 : 2805 13.
8. Veves A, Akbari CM, Primavera J, Donaghue VM, Zacharoulis D, Chrzan JS, DeGirolami U, LoGerfo FW, Freeman R. Endothelial dysfunction and the expression of the endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998 47 : 457 63.
9. Vlassara H. Advanced glycation in health and disease: role of the modern environment. Ann NY Acad Sci 2005 1043 : 452 60.
10. Peppa M, Uribarri J, Vlassara H. Aging and glycoxidant stress. Hormones 2008 7 : 123 32.
11. Peppa M, Uribarri J, Vlassara H. Glucose and the advanced glycosylation end products. In : Veves A, editor. Diabetes and cardiovascular disease. 2nd ed. Totowa, NJ : Humana Press, 2005 : 81 102.
12. Peppa M, SA Raptis. Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev 2008 4 : 1 9.
13. Peppa M, Vlassara H. Advanced glycation end products and diabetic complications: a general overview. Hormones 2005 4 : 28 3.
14. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates N (epsilon)-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999 104 : 103 13.
15. Vander Jagt DL, Hassebrook RK, Hunsaker LA, Brown WM, Royer RE. Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications. Chem Biol Interact 2001 130-132 : 549 62.
16. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007 62 : 427 33.
17. Nicholl ID, Stitt AW, Moore JE, Ritchie AJ, Archer DB, Bucala R. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med 1998 4 : 594 601.
18. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J, Vlassara H. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004 104 : 1287 91.
19. Silván JM, van de Lagemaat J, Olano A, Del Castillo MD. Analysis and biological properties of amino acid derivates formed by Maillard reaction in foods. J Pharm Biomed Anal 2006 41 : 1543 51.
20. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002 8 : 337 46.
21. Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J, Vlassara H. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004 110 : 285 91.
22. Cai W, He JC, Zhu L, Chen X, Wallenstein S, Striker GE, Vlassara H. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 2007 170 : 1893 902.
23. Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003 52 : 1441 8.
24. Hofmann SM, Dong HJ, Li Z, Cai W, Altomonte J, Thung SN, Zeng F, Fisher EA, Vlassara H. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002 51 : 2082 9.
25. Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2002 51 : 2082 9.
26. Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, Fisher EA, Vlassara H. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003 168 : 213 20.
27. Lin RY, Reis ED, Dore AT, Lu M, Ghodsi N, Fallon JT, Fisher EA, Vlassara H. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002 163 : 303 11.
28. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002 18 : 224 39.
29. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002 99 : 15596 601.
30. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003 14 : 728 31.
31. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, Baliga S, Vassalotti JA, Vlassara H. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003 42 : 532 8.
32. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004 43 : 690 5.
33. Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007 30 : 2579 82.
34. Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007 30 : 2579 82.
35. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006 29 : 2064 71.
36. Vlassara H, Uribarri J, Cai W, Striker G. AGE homeostasis: exogenous oxidants and innate defenses. Ann NY Acad Sci Ann NY Acad Sci 2008 1126 : 46 52.
37. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 2005 1043 : 461 6.
38. Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006 103 : 13801 6.
39. Cai W, He JC, Zhu L, Chen X, Striker GE, Vlassara H. AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 2008 294 : C145 52.
40. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999 341 : 738 46.
41. Calvin M. Cutaneous wound repair. Wounds 1998 10 : 12 32.
42. Peter A., Ward MD, Alex B, Lentsch P. The acute inflammatory response and its regulation. Arch Surg 1999 134 : 666 9.
43. Gailit J, Clark RA. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol 1994 6 : 717 25.
44. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001 69 : 513 21.
45. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994 8 : 504 12.
46. Chen J, Kasper M, Heck T, Nakagawa K, Humpert PM, Bai L, Wu G, Zhang Y, Luther T, Andrassy M, Schiekofer S, Hamann A, Morcos M, Chen B, Stern DM, Nawroth PP, Bierhaus A. Tissue factor as a link between wounding and tissue repair. Diabetes 2005 54 : 2143 54.
47. Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000 49 : 1451 8.
48. Bagdade JD, Stewart M, Walters E. Impaired granulocyte adherence. A reversible defect in host defense with poorly controlled diabetes. Diabetes 1978 27 : 677 81.
49. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in nonhealing and healing chronic leg ulcers. Wound Repair Regen 2000 8 : 13 25.
50. Wetzler C, Kämpfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol 2000 115 : 245 53.
51. Chang FY, Shaio MF. Respiratory burst activity of monocytes from patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995 29 : 121 7.
52. Soneja A, Drews M, Malinski T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep 2005 57 (Suppl.) : 108 19.
53. Li Y, Ferrante A, Poulos A, Harvey DP. Neutrophil oxygen radical generation: synergistic responses to tumor necrosis factor and mono-polyunsaturated fatty acids. J Clin Invest 1996 97 : 1605 9.
54. Musalmah M, Fairuz AH, Gapor MT, Ngah WZ. Effect of vitamin E on plasma malondialdehyde, antioxidant enzyme levels and the rates of wound closures during wound healing in normal and diabetic rats. Asia Pac J Clin Nutr 2002 11 (Suppl. 7) : S448 51.
55. O'Toole EA, Marinkovich MP, Peavey CL, Amieva MR, Furthmayr H, Mustoe TA, Woodley DT. Hypoxia increases human keratinocyte motility on connective tissue. J Clin Invest 1997 100 : 2881 91.
56. Schultz G, Rotatori DS, Clark W. EGF and TGF-alpha in wound healing and repair. J Cell Biochem 1991 45 : 346 52.
57. Shirakata Y, Kimura R, Nanba D, Iwamoto R, Tokumaru S, Morimoto C, Yokota K, Nakamura M, Sayama K, Mekada E, Higashiyama S, Hashimoto K. Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. J Cell Sci 2005 118 (Pt 11) : 2363 70.
58. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Circ Res 1995 77 : 638 43.
59. Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995 270 : 12607 13.
60. Bates DO, Jones RO. The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds 2003 2 : 107 20.
61. Katz MH, Alvarez AF, Kirsner RS, Eaglstein WH, Falanga V. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol 1991 25 (Part 1) : 1054 8.
62. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003 83 : 835 70.
63. Lynch SE, Nixon JC, Colvin RB, Antoniades HN. Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci USA 1987 84 : 7696 700.
64. Campbell EJ, Cury JD, Shapiro SD, Goldberg GI, Welgus HG. Neutral proteases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J Immunol 1991 146 : 1286 93.
65. Pilcher BK, Wang M, Qin XJ, Parks WC, Senior RM, Welgus HG. Role of matrix metalloproteinases and their inhibition in cutaneous wound healing and allergic contact hypersensitivity. Ann NY Acad Sci 1999 878 : 12 24.
66. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999 285 : 1028 32.
67. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007 23 : 435 61.
68. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002 277 : 4589 92.
69. Yamada KM. Fibronectin peptides in cell migration and wound repair. J Clin Invest 2000 105 : 1507 9.
70. Xu J, Clark RA. Extracellular matrix alters PDGF regulation of fibroblast integrins. J Cell Biol 1996 132 : 239 49.
71. Greiling D, Clark RA. Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. J Cell Sci 1997 110 (Part 7) : 861 70.
72. Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986 261 : 4337 45.
73. Doxey DL, Ng MC, Dill RE, Iacopino AM. Platelet-derived growth factor levels in wounds of diabetic rats. Life Sci 1995 57 : 1111 23.
74. Altavilla D, Saitta A, Cucinotta D, Galeano M, Deodato B, Colonna M, Torre V, Russo G, Sardella A, Urna G, Campo GM, Cavallari V, Squadrito G, Squadrito F. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 2001 50 : 667 74.
75. Loot MA, Kenter SB, Au FL, van Galen WJ, Middelkoop E, Bos JD, Mekkes JR. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-1, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002 81 : 153 60.
76. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction of the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003 162 : 303 12.
77. Tsuboi R, Rifkin DB. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impaired db/db mice. J Exp Med 172 : 245 51.
78. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999 7 : 442 52.
79. Lobmann R, Pap T, Ambrosch A, Waldmann K, König W, Lehnert H. Differential effects of PDGF-BB on matrix metalloproteinases and cytokine release in fibroblasts of type 2 diabetic patients and normal controls in vitro. J Diabetes Complicat 2006 20 : 105 12.
80. Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T, Wertheimer E. Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes 2001 50 : 1627 35.
81. Desmoulière A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during transition between granulation tissue and scar. Am J Pathol 1995 146 : 56 66.
82. Al-Mashat HA, Kandru S, Liu R, Behl Y, Desta T, Graves DT. Diabetes enhances mRNA levels of propapoptotic genes and caspase activity, which contribute to impaired wound healing. Diabetes 2006 55 : 487 95.
83. Liu R, Desta T, He H, Graves DT. Diabetes alters the response to bacteria by enhancing fibroblast apoptosis. Endocrinology 2004 145 : 2997 3003.
84. Grinnell F. Fibroblasts, myofibroblasts and wound contraction. J Cell Biol 1994 124 : 401 4.
85. Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008 14 : 953 61.
86. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005 48 : 1637 44.
87. Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002 50 : 37 57.
88. Toth C, Rong LL, Yang C, Martinez J, Song F, Ramji N, Brussee V, Liu W, Durand J, Nguyen MD, Schmidt AM, Zochodne DW. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008 57 : 1002 17.
89. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001 108 : 949 55.
90. Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammami MM, Schmidt AM, Stern DM, Al-Mohanna FA. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002 71 : 433 44.
91. Liu BF, Miyata S, Kojima H, Uriuhara A, Kusunoki H, Suzuki K, Kasuga M. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes 1999 48 : 2074 82.
92. Teixeira AS, Caliari MV, Rocha OA, Machado RD, Andrade SP. Aminoguanidine prevents impaired healing and deficient angiogenesis in diabetic rats. Inflammation 1999 23 : 569 81.
93. Berlanga J, Cibrian D, Guillén I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequin JF, Ajamieh H, Urquiza D, Ahmed N, Thornalley PJ. Methylglyoxal administration induces diabetes-like microvascular changes and pertubs the healing process of cutaneous wounds. Clin Sci (Lond) 2005 109 : 83 95.
94. Wong RK, Pettit AI, Quinn PA, Jennings SC, Davies JE, Ng LL. Advanced glycation end products stimulate an enhanced neutrophil respiratory burst mediated through the activation of cytosolic phospholipase A2 and generation of arachidonic acid. Circulation 2003 108 : 1858 64.
95. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994 269 : 9889 97.
96. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001 280 : E685 94.
97. Li Y, Ferrante A, Poulos A, Harvey DP. Neutrophil oxygen radical generation: synergistic responses to tumor necrosis factor and mono-polyunsaturated fatty acids. J Clin Invest 1996 97 : 1605 9.
98. Rojas A, Caveda L, Romay C, López E, Valdés S, Padrón J, Glaría L, Martínez O, Delgado R. Effect of advanced glycosylation end products on the induction of nitric oxide synthase in murine macrophages. Biochem Biophys Res Commun 1996 225 : 358 62.
99. Schmidt AM, Weidman E, Lalla E, Yan SD, Hori O, Cao R, Brett JG, Lamster IB. Advanced glycation end products (AGEs) induce oxidant stress in the gingiva: a potential mechanism underlying accelerated periodontal disease associated with diabetes. J Periodontal Res 1996 31 : 508 15.
100. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques. Circulation 2003 108 : 1070 7.
101. Lalla E, Lamster IB, Feit M, Huang L, Spessot A, Qu W, Kislinger T, Lu Y, Stern DM, Schmidt AM. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000 105 : 1117 24.
102. Morita K, Urabe K, Moroi Y, Koga T, Nagai R, Horiuchi S, Furue M. Migration of keratinocytes is impaired on glycated collagen I. Wound Repair Regen 2005 13 : 93 101.
103. Kuzuya M, Satake S, Ai S, Asai T, Kanda S, Ramos MA, Miura H, Ueda M, Iguchi A. Inhibition of angiogenesis on glycated collagen lattices. Diabetologia 1998 41 : 491 9.
104. Paul RG, Bailey AJ. The effect of advanced glycation end product formation upon cell matrix interactions. Int J Biochem Cell Biol 1993 31 : 653 60.
105. McCarthy AD, Uemura T, Etcheverry SB, Cortizo AM. Advanced glycation end products interfere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. Int J Biochem Cell Biol 2004 36 : 840 8.
106. Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 1998 106 : 1 56.
107. Fujimori E. Cross-linking and fluorescence changes of collagen by glycation and oxidation. Biochim Biophys Acta 1989 998 : 105 10.
108. Niu Y, Xie T, Ge K, Lin Y, Lu S. Effects of extracellular matrix glycosylation on proliferation and apoptosis of human dermal fibroblasts via the receptor for advanced glycosylated end products. Am J Dermatopathol 2008 30 : 344 51.
109. Ivanov G, Kyurkchiev S. Effect of advanced glycosylation end products on the activity of integrins expressed on U937 cell. Hum Immunol 1998 59 : 325 30.
110. Kazuhiro Y, Tomohide O, Tomonobu Y, Masatoshi B. Inhibitory effect of peptide free forms of advanced glycation end products on the proliferation and extracellular matrix production of cultured cells. J Health Sci 2001 47 : 296 301.
111. Okano Y, Masaki H, Sakurai H. Dysfunction of dermal fibroblasts induced by advanced glycation end-products (AGEs) and the contribution of a nonspecific interaction with cell membrane and AGEs. J Dermatol Sci 2002 29 : 171 80.
112. Alikhani Z, Alikhani M, Boyd CM, Nagao K, Trackman PC, Graves DT. Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem 2005 280 : 12087 95.
113. Alikhani M, Maclellan CM, Raptis M, Vora S, Trackman PC, Graves DT. Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am J Physiol Cell Physiol 2007 292 : C850 6.
114. Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007 40 : 345 53.
115. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994 94 : 110 7.
116. Duraisamy Y, Slevin M, Smith N, Bailey J, Zweit J, Smith C, Ahmed N, Gaffney J. Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis 2001 4 : 277 88.
117. Portero-Otín M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, Nègre-Salvayre A. Advanced glycation end product precursors impair epidermal growth factor receptor signalling. Diabetes 2002 51 : 1535 42.
118. Teixeira AS, Andrade SP. Glucose-induced inhibition of angiogenesis in the rat sponge granuloma is prevented by aminoguanidine. Life Sci 1999 64 : 655 62.
119. Yavuz D, Tutepe H, Cetinel S, Uyar S, Kaya H, Haklar G, Civelek S, Deyneli O, San T, Burçak G, Akalin S. Collagen ultrastructure and TGF-beta1 expression preserved with aminoguanidine during wound healing in diabetic rats. Endocr Res 2005 31 : 229 43.
120. Howard EW, Benton R, Ahern-Moore J, Tomasek JJ. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp Cell Res 1996 228 : 132 7.
121. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002 3 : 349 63.